US Patent

US11389511 — Controlled-release CNP agonists with reduced side-effects

Method of Use · Assigned to Ascendis Pharma Growth Disorders AS · Expires 2037-01-05 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a pharmaceutical composition that reduces side effects of a controlled-release CNP agonist.

USPTO Abstract

The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4425`	—
`U-4425`	—
`U-4425`	—

Patent Metadata

Patent number: US11389511
Jurisdiction: US
Classification: Method of Use
Expires: 2037-01-05
Drug substance claim: No
Drug product claim: Yes
Assignee: Ascendis Pharma Growth Disorders AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.